Suptavumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSuptavumab
Drug Alias NameSuptavumabum舒他伏单抗H1H3592P3REGN-2222A0ZE931055 (UNII code) +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionRespiratory syncytial virus F protein inhibitors
TargetsRespiratory syncytial virus F protein
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaPanama +[19] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals IncSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegeneron Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A
Related LinksN/A